Nurse Practitioner in Richfield, UT Accepting Medicare

5 Nurse Practitioner nurses found. Showing 1 - 5

Kylee Kay Dalton, FNP-C Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 440 S Main St, Richfield, UT 84701 Phone: 435-893-6800

Miss Rebekah Amy Patterson, FNP Nurse Practitioner - Family Medicare: May Accept Medicare Assignments Practice Location: 850 N Main St, Richfield, UT 84701 Phone: 435-896-9561    Fax: 435-896-9564

Lisa Sanders, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 275 N 200 W, Richfield, UT 84701 Phone: 435-893-5916

Ryan Richard Blad, FNP-C Nurse Practitioner - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 882 N Main St Ste 2, Richfield, UT 84701 Phone: 435-287-2444    Fax: 435-287-2446

Bridget Bennett, APRN Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 879 N Main St, Richfield, UT 84701 Phone: 435-896-9561    Fax: 435-896-9564

News Archive

Researchers discover a way to move precision immunotherapy forward for multiple myeloma

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.

PNP reaches several major objectives in cancer therapeutic product development

PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer.

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

Potential new method of breast cancer treatment using androgen receptor

Scientists may have discovered a new therapeutic approach to treat ER+ breast cancer using androgen receptor-stimulating drugs.

Read more Medical News

› Verified 7 days ago